Literature DB >> 16386664

Comparison of B-type natriuretic peptides for assessment of cardiac function and prognosis in stable ischemic heart disease.

Mark Richards1, M Gary Nicholls, Eric A Espiner, John G Lainchbury, Richard W Troughton, John Elliott, Christopher M Frampton, Ian G Crozier, Timothy G Yandle, Robert Doughty, Stephen MacMahon, Norman Sharpe.   

Abstract

UNLABELLED: In 1,049 patients with stable ischemic heart disease (IHD), brain natriuretic peptide (BNP) and amino terminal pro-brain natriuretic peptide (NTproBNP) correlated closely (r = 0.09, p < 0.001) and were similarly related to left ventricular ejection fraction (LVEF) (r = -0.50 and -0.46, respectively), age (0.44 and 0.47), and creatinine clearance (-0.51 and -0.51). Receiver-operating characteristic curves for detection of LVEF <30% were similar (area under the curves = 0.83 and 0.80, both p < 0.001), and both peptides had strong negative predictive value (95% and 94%). Both independently predicted all-cause mortality and/or heart failure with closely overlapping event-free survival curves; BNP and NTproBNP display strong, near-identical test performance in ruling about severely reduced LVEF and in prediction of all-cause mortality or heart failure in stable IHD.
OBJECTIVES: The aim of this work was to test B-type natriuretic peptides for assessment of function and prognosis in stable ischemic heart disease (IHD) and to compare brain natriuretic peptide (BNP) with amino terminal pro-brain natriuretic peptide (NTproBNP), including the relative effects of age and renal function on test performance.
BACKGROUND: Brain natriuretic peptide and NTproBNP are emerging diagnostic and prognostic markers in heart failure and acute coronary syndromes. Their performance in assessing function and prognosis in stable IHD is unknown. Whether one marker is superior and the relative effects of age and renal function on test performance are uncertain.
METHODS: In 1,049 patients with stable IHD, left ventricular ejection fraction (LVEF) was measured by radionuclide scanning and creatinine clearance estimated by the Cockroft-Gault equation. Age, gender, and body mass index were recorded. Twelve-month all-cause mortality or admission with heart failure was prospectively recorded; BNP and NTproBNP were measured by radioimmunoassay.
RESULTS: Brain natriuretic peptide and NTproBNP correlated closely (r = 0.90, p < 0.001) and had similar relationships to LVEF (r = -0.50 and -0.46, respectively, both p < 0.001), age (0.44 and 0.47, both p < 0.001), and creatinine clearance (-0.51 and -0.51, both p < 0.001). Areas under receiver-operating characteristic curves for detection of LVEF <30% were similar (0.83 and 0.80, both p < 0.001) with strong negative predictive values for both (95% and 94%). Both markers independently predicted the clinical end point with closely overlapping event-free survival curves.
CONCLUSIONS: In stable IHD, BNP and NTproBNP display strong and near-identical test performance in ruling out severely reduced LVEF and in prediction of all-cause mortality or heart failure despite significant effects of age, gender, and renal function on levels of both markers.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16386664     DOI: 10.1016/j.jacc.2005.06.085

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  38 in total

1.  Impact of the look AHEAD intervention on NT-pro brain natriuretic peptide in overweight and obese adults with diabetes.

Authors:  Alain G Bertoni; Lynne E Wagenknecht; Dalane W Kitzman; Santica M Marcovina; Julia T Rushing; Mark A Espeland
Journal:  Obesity (Silver Spring)       Date:  2011-09-29       Impact factor: 5.002

Review 2.  Novel Biomarkers of Subclinical Cardiac Dysfunction in the General Population.

Authors:  Kamal Shemisa; Anish Bhatt; Daniel Cheeran; Ian J Neeland
Journal:  Curr Heart Fail Rep       Date:  2017-08

Review 3.  Neurohormonal modulation in heart failure of ischemic etiology: correlates with left ventricular remodeling.

Authors:  Roberto Latini; Serge Masson; Lidia Staszewsky; Simona Barlera
Journal:  Curr Heart Fail Rep       Date:  2006-12

4.  National Academy of Clinical Biochemistry (NACB) laboratory medicine guidelines on the clinical utilization and analytical issues for cardiac biomarker testing in heart failure.

Authors:  John Beilby
Journal:  Clin Biochem Rev       Date:  2008-08

5.  Use of B-type natriuretic peptide as a screening tool for left ventricular diastolic dysfunction in rheumatoid arthritis patients without clinical cardiovascular disease.

Authors:  Cynthia S Crowson; Elena Myasoedova; John M Davis; Veronique L Roger; Barry L Karon; Daniel Borgeson; Richard J Rodeheffer; Terry M Therneau; Sherine E Gabriel
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-05       Impact factor: 4.794

Review 6.  The Confounding Effects of Non-cardiac Pathologies on the Interpretation of Cardiac Biomarkers.

Authors:  Marin Nishimura; Alison Brann; Kay-Won Chang; Alan S Maisel
Journal:  Curr Heart Fail Rep       Date:  2018-08

7.  Sleep study-guided multidisciplinary therapy (SGMT) for patients with acute coronary syndrome: Trial rationale and design.

Authors:  Ai-Ping Chua; Chieh-Yang Koo; William Kristanto; Maria Victoria Jane Macalalag Parot; Eugene Siang-Joo Tan; Esther Hui-Ting Koh; Munirah Binte Abd Gani; Pipin Kojodjojo; Tun-Oo Han; Siew-Pang Chan; Jenny Pek-Ching Chong; Christopher Frampton; Arthur Mark Richards; Chi-Hang Lee
Journal:  Clin Cardiol       Date:  2018-06-06       Impact factor: 2.882

Review 8.  Secondary prevention strategies for coronary heart disease.

Authors:  Shepard D Weiner; LeRoy E Rabbani
Journal:  J Thromb Thrombolysis       Date:  2010-01       Impact factor: 2.300

9.  B-type natriuretic peptide and C-reactive protein in the prediction of atrial fibrillation risk: the CHARGE-AF Consortium of community-based cohort studies.

Authors:  Moritz F Sinner; Katherine A Stepas; Carlee B Moser; Bouwe P Krijthe; Thor Aspelund; Nona Sotoodehnia; João D Fontes; A Cecile J W Janssens; Richard A Kronmal; Jared W Magnani; Jacqueline C Witteman; Alanna M Chamberlain; Steven A Lubitz; Renate B Schnabel; Ramachandran S Vasan; Thomas J Wang; Sunil K Agarwal; David D McManus; Oscar H Franco; Xiaoyan Yin; Martin G Larson; Gregory L Burke; Lenore J Launer; Albert Hofman; Daniel Levy; John S Gottdiener; Stefan Kääb; David Couper; Tamara B Harris; Brad C Astor; Christie M Ballantyne; Ron C Hoogeveen; Andrew E Arai; Elsayed Z Soliman; Patrick T Ellinor; Bruno H C Stricker; Vilmundur Gudnason; Susan R Heckbert; Michael J Pencina; Emelia J Benjamin; Alvaro Alonso
Journal:  Europace       Date:  2014-07-18       Impact factor: 5.214

10.  The Importance of Amino-terminal pro-Brain Natriuretic Peptide Testing in Clinical Cardiology.

Authors:  Van Kimmenade
Journal:  Biomark Insights       Date:  2007-02-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.